Institutional Career Development Core

机构职业发展核心

• 批准号: 10693371
• 负责人: Catherine Lee Hough
• 金额: $ 130.41万
• 依托单位: OREGON HEALTH & SCIENCE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-09-02 至 2027-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10693371
• 关键词: Active Learning; Clinical; Clinical Competence; Clinical Research; Communication; Communities; Competence; Consultations; Development; Development Plans; Educational Curriculum; Enrollment; Faculty; Foundations; Funding; Goals; Grant; Grant Review; Institution; K-Series Research Career Programs; Laboratories; Leadership; Manuscripts; Mentors; Mentorship; Oregon; Outcome; Patients; Qualitative Methods; Research; Scholars Program; Technology; Time; Training; Training Programs; Translating; Translational Research; Universities; Writing; career; career development; community engagement; design; expectation; experience; peer networks; programs; recruit; research and development; skills; translational scientist

I. Institutional Career Development Core: Project Summary The KL2 training program within OCTRI is built on a strong foundation of excellent scholar outcomes, with a strong rate of progression to independent funding, a diverse pool of faculty scholars, and supportive mentorship. Scholars and the mentor pool are recruited from OHSU and our academic partners, University of Oregon, Oregon State University, and Portland State University. The goal of the OCTRI KL2 program is to train a corps of clinical and translational scientists in the skills and competencies of clinical and translational research who can employ cutting edge technologies to translate discoveries made in the laboratory to the patient and the community. Through this program, we will select outstanding early faculty who are committed to developing a research career; each of the scholars will participate in a mentored research experience with a minimum protected time of 0.75 FTE. Scholars will develop a career development plan with the aid of a mentor team – which will include a designated primary mentor – to assist with career development, networking, manuscript writing, and grant development. Scholars form an independent development plan with their mentor and program leadership to enhance their research competency. Training is individualized and scholars participate in activities to enhance their research and career development needs: development of research competencies in clinical and translational research, professional activities, and experiential learning. Scholars enroll in the curriculum of the Master of Clinical Research program; all scholars must participate in training in qualitative methods, scientific communication, and research leadership. Professional development includes opportunities through the OCTRI Scholar program for peer networking, Design Studio, and access to research consultation. Community engagement will be emphasized in research development, with all scholars gaining experience with stakeholders. Scholars will also gain experience with grant writing and grant review. The goal of this program is to produce an independent, transdisciplinary clinical and translational researcher. The expectation is that scholars will move to an independent K award at the end of the KL2 funding period.

I.机构职业发展核心：项目摘要 OCTRI内的KL 2培训计划建立在优秀学者成果的坚实基础上， 发展到独立资助的强劲速度，教师学者的多元化池，和支持 导师制学者和导师库是从OHSU和我们的学术合作伙伴， 俄勒冈州、俄勒冈州州立大学和波特兰州立大学。 OCTRI KL 2计划的目标是培养一支临床和转化科学家队伍， 临床和转化研究的能力，他们可以采用尖端技术来翻译 将实验室中的发现带给患者和社区。通过这个项目，我们将选择 杰出的早期教师谁致力于发展研究事业;每个学者将 参与指导研究经验，最低保护时间为0.75 FTE。学者项目的学生将 在导师团队的帮助下制定职业发展计划-其中包括指定的主要 导师-协助职业发展、建立关系网、撰写手稿和发展赠款。 学者们与他们的导师和项目领导形成一个独立的发展计划，以提高他们的 研究能力。培训是个性化的，学者参加活动，以加强他们的研究 和职业发展需要：发展临床和转化研究的研究能力， 专业活动和经验学习。学者报名参加临床医学硕士课程 研究计划;所有学者必须参加定性方法，科学交流， 研究领导力。职业发展包括通过OCTRI奖学金的机会 计划同行网络，设计工作室，并获得研究咨询。社区参与将 在研究开发中强调，所有学者都能获得与利益相关者的经验。学者项目的学生将 也获得经验与赠款写作和赠款审查。 该计划的目标是产生一个独立的，跨学科的临床和翻译研究人员。 预计学者将在KL 2资助期结束时转向独立的K奖。

项目成果

[18F]-fluoromisonidazole (FMISO) PET/MRI hypoxic fraction distinguishes neuroinflammatory pseudoprogression from recurrent glioblastoma in patients treated with pembrolizumab.

[18F]-氟米索硝唑 (FMISO) PET/MRI 缺氧分数可区分接受派姆单抗治疗的患者的神经炎症假性进展和复发性胶质母细胞瘤。

• DOI: 10.1093/nop/npac021
• 发表时间: 2022
• 期刊: Neuro-oncology practice
• 影响因子: 2.7
• 作者: BarajasJr,RamonF;Ambady,Prakash;Link,Jeanne;Krohn,KennethA;Raslan,Ahmed;Mallak,Nadine;Woltjer,Randy;Muldoon,Leslie;Neuwelt,EdwardA
• 通讯作者: Neuwelt,EdwardA

A targeted combinatorial therapy for Ewing's sarcoma.

• DOI: 10.1016/j.nano.2021.102446
• 发表时间: 2021-10
• 期刊: Nanomedicine : nanotechnology, biology, and medicine
• 作者: Sabei FY;Taratula O;Albarqi HA;Al-Fatease AM;Moses AS;Demessie AA;Park Y;Vogel WK;Esfandiari Nazzaro E;Davare MA;Alani A;Leid M;Taratula O
• 通讯作者: Taratula O

A Single Mechanism for Global and Selective Response Inhibition under the Influence of Motor Preparation.

运动准备影响下全局和选择性反应抑制的单一机制。

• DOI: 10.1523/jneurosci.0607-20.2020
• 发表时间: 2020
• 期刊: The Journal of neuroscience : the official journal of the Society for Neuroscience
• 作者: Raud,Liisa;Huster,RenéJ;Ivry,RichardB;Labruna,Ludovica;Messel,MariS;Greenhouse,Ian
• 通讯作者: Greenhouse,Ian

Resting coronary flow drives the daily pattern in coronary flow reserve in patients with chest pain without obstructive epicardial stenosis.

• DOI: 10.3389/fcvm.2023.1057692
• 发表时间: 2023
• 期刊: FRONTIERS IN CARDIOVASCULAR MEDICINE
• 影响因子: 3.6
• 作者: Thosar, Saurabh S. S.;Taqui, Sahar;Davidson, Brian;Belcik, Todd;Hodovan, James;Rice, Sean P. M.;Lindner, Jonathan R. R.
• 通讯作者: Lindner, Jonathan R. R.

Targeted Transcriptional Analysis of IgA Vasculitis, IgA Nephropathy, and IgA-Dominant Infection-Related Glomerulonephritis Reveals Both Distinct and Overlapping Immune Signatures.

• DOI: 10.34067/kid.0000000000000123
• 发表时间: 2023-06-01
• 期刊: Kidney360
• 作者: Kung VL;Avasare R;Friedman MA;Koon SM;Neff TL;Protzek S;Corless C;Krajbich V;Setthavongsack N;Ditmore R;Woltjer R;Andeen NK
• 通讯作者: Andeen NK